SUBSCRIBE
SUBSCRIBE

Alnylam Pharmaceuticals

NEWS
Business
Alnylam Jumps on $1B RNAi Pact With Vir Biotechnology
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
October 18, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi
Business
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam
September 21, 2017
 · 
2 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals
September 20, 2017
 · 
3 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges
September 7, 2017
 · 
2 min read
Policy
Sparring Over Trade Secrets, Dicerna Brings New Antitrust Suit Against Alnylam
August 11, 2017
 · 
1 min read
Drug Development
Could Alnylam Have An Edge On This Smaller Biotech In Rare Disease?
July 11, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Why All Eyes Will be on Alnylam and Any Updates of Its APOLLO Phase III Trial This Friday
May 11, 2017
 · 
2 min read
Genetown
Alnylam’s Patisiran, Chronicle Of A Death Foretold
April 11, 2017
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Business
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
February 11, 2021
 · 
33 min read
Business
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
January 28, 2021
 · 
2 min read
Genetown
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
 · 
2 min read
Genetown
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2020
 · 
16 min read
Genetown
Alnylam to Webcast Virtual R&D Day
December 8, 2020
 · 
2 min read
Business
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
December 8, 2020
 · 
8 min read
Genetown
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
December 7, 2020
 · 
11 min read
Drug Development
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 3, 2020
 · 
10 min read
Genetown
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
November 25, 2020
 · 
1 min read
FDA
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
November 24, 2020
 · 
19 min read
Load More